Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.67 Consensus Target Price from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been given a consensus rating of “Buy” by the eight ratings firms that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.67.

Several equities research analysts have commented on the company. HC Wainwright initiated coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued a “buy” rating and a $6.00 target price on the stock. Raymond James initiated coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price target on the stock. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective for the company. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Finally, Rodman & Renshaw started coverage on shares of Trevi Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective on the stock.

Trevi Therapeutics Stock Up 0.3 %

Shares of Trevi Therapeutics stock opened at $3.34 on Tuesday. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The business has a 50 day moving average of $3.04 and a 200 day moving average of $2.92. The company has a market cap of $242.45 million, a PE ratio of -9.82 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter in the previous year, the company posted ($0.07) EPS. On average, research analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares in the company, valued at $608,069.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Thomas Sciascia sold 18,660 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now directly owns 220,315 shares of the company’s stock, valued at approximately $608,069.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The disclosure for this sale can be found here. Insiders have sold a total of 40,355 shares of company stock valued at $116,663 over the last ninety days. 24.37% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its position in shares of Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the last quarter. Logos Global Management LP increased its stake in Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares during the period. Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics in the second quarter worth approximately $4,395,000. Hsbc Holdings PLC purchased a new stake in Trevi Therapeutics in the second quarter worth about $61,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Trevi Therapeutics by 217.6% during the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after purchasing an additional 49,475 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.